Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

4.0%

2 terminated/withdrawn out of 50 trials

Success Rate

90.5%

+3.9% vs industry average

Late-Stage Pipeline

20%

10 trials in Phase 3/4

Results Transparency

32%

6 of 19 completed trials have results

Key Signals

15 recruiting6 with results

Enrollment reporting

Analytics

N/A

16(55.2%)

Phase 3

5(17.2%)

Phase 4

5(17.2%)

Phase 1/2

1(3.4%)

Phase 2

1(3.4%)

Phase 2/3

1(3.4%)

29Total

N/A(16)

Phase 3(5)

Phase 4(5)

Phase 1/2(1)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (50)

Showing 20 of 50 trials

NCT06905834Phase 2Not Yet Recruiting

Evaluation of Allogenic Mesenchymal Stem Cell (MSC) Injection Therapy for Refractory Graft-versus-Host Disease (GVHD) Unresponsive to Conventional Treatments

Role: lead

NCT07268391Not ApplicableRecruiting

Using Advanced CT Scans and Blood Markers to Better Understand Heart Damage and Recovery After a Heart Attack

Role: lead

NCT06272539Not ApplicableCompleted

Spinal Cord Stimulation Combined With Exercise in Persistent Spinal Pain Syndrome

Role: collaborator

NCT07277387Recruiting

Plasma Host-Microbe Proteomics to Predict Complications in High-risk Febrile Neutropenia

Role: lead

NCT04929418Not ApplicableCompleted

Differential Adaptation of Renal Function in Intense Physical Exercise

Role: collaborator

NCT07394790Not ApplicableRecruiting

Effectiveness of a Physical Exercise Prescription Program in Primary Care for Adults Aged 65 and Older: PREFIS-AP

Role: lead

NCT06977295Recruiting

Evaluation of a Diagnostic Software for Coronary Artery Disease Using Retrospective CCTA Data (CODEX-1 Study)

Role: lead

NCT06378190Phase 1/2Recruiting

Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology

Role: lead

NCT07015892Phase 3Recruiting

Dose-Escalation Radiotherapy in Limited-Stage Small Cell Lung Cancer: A Phase III Randomized Trial

Role: lead

NCT07295483Recruiting

Predictors of Long-Term Evolution in Long COVID; 4-Year Follow-Up. (BioICOPER Follow-up Study)

Role: lead

NCT07195331Phase 4Recruiting

Comparison Between Standard and Reduced Doses of Indocyanine Green in Fluorescence Cholangiography During Laparoscopic Cholecystectomy.

Role: lead

NCT07447375Not ApplicableRecruiting

Exercise During Hemodialysis: Impact on Sarcopenia and Sleep Quality

Role: collaborator

NCT07348484Not Yet Recruiting

Urinary Biomarker-Based Diagnostic and Monitoring System for Chronic Kidney Disease and Real-World Effectiveness of SGLT2 Inhibitors

Role: lead

NCT07303361Not ApplicableCompleted

Effect of Active Mandibular Techniques and Specific Cranio-cervical Therapeutic Exercise in Patients With Temporomandibular Disorders and Bruxism (AMaCe-TB)

Role: lead

NCT06188910Not ApplicableCompleted

Neurofeedback and Nomophobia in Young Adults

Role: collaborator

NCT07064330Recruiting

Next-gen Flow Cytometry to Find Immune Profiles, Treatment Response, and Toxicity Markers in Skin Cancer Patients Treated With Cemiplimab.

Role: lead

NCT05419947Phase 4Completed

Clinical Trial for the Optimization of Indocyanine Green Administration in NIRF-C During L.Cholecystectomy.

Role: collaborator

NCT03739476Phase 3Terminated

Clinical Trial With Quetiapine Prophylaxis Postoperative Delirium in High Risk Surgical Patients

Role: collaborator

NCT06379945Recruiting

Unified platforM for a Better integRal Evaluation of MyeLodyspLastic Syndromes in SpAin-Strategy for Unraveling Personalized genoMic Medicine in Public heAlth System (UMBRELLA-SUMMA)

Role: lead

NCT06382844Recruiting

Novel Flow-cytometry Approaches to Improve the Detection of Tumor Cells in CTCL

Role: lead